Model: | MOS 1392-21-8 39405-35-1 |
CAS: | 1392-21-8 39405-35-1 |
Molecular formula: | C41H69NO13 |
Molecular weight: | 783.99 |
Water solubility: | ethanol: 50 mg/mL, clear to slightly hazy, light-yellow |
Synonyms: | Acetyl Kitasamycin |
Refractive index: | 1.532 |
Kitasamycin (CAS: 1392-21-8 39405-35-1)
ITEM | STANDARD | RESULT |
Appearance | A white or almost white powder | Conform |
Identification | ||
Chemical reaction | Positive | Positive |
LC | Four test solution and the control
solution appears A5, A4, A1, A13 peak retention time consistent peaks |
Four test solution and the control
solution appears A5, A4, A1, A13 peak retention time consistent peaks |
Alkalinity | 8.0 ~ 10.0 | 8.8 |
Residue on Ignition | ≤ 0.5% | 0.2% |
Water | ≤ 3.0% | 1.8% |
Kitasamycin components | Kitasamycin A1: 3.0%-15.0% | 10.4% |
Kitasamycin A4: 5%-25% | 11% | |
Kitasamycin A5: 35%-70% | 48% | |
Kitasamycin A13: 3.0%-15.0% | 7.9% | |
KitasamycinA (9+8+7+6+5+4+1+3+13): ≥85% | 98% | |
Assay | Not less than 1300u/mg calculated with reference
to the anhydrous substances |
1651u/mg
1621u/mg(wet) |
Kitasamycin (INN) is a macrolide antibiotic. It is produced by Streptomyces kitasatoensis. The medicine has
antimicrobial activity against a wide spectrum of pathogens. There are several generic names of this drug such
as- •Kitasamycin (OS: BAN, JAN, USAN) •Kitasamycine (OS: DCF) •C 637 (IS) •Katasamycin (IS) •Leucomycin
(IS) •Kitasamycin (PH: JP XV) •Kitasamycin Acetate (OS: JAN) •Leucomycin Acetate (IS) •Kitasamycin Acetate
(PH: JP XV) •Kitasamycin Tartrate (OS: JAN) •Leucomycin Tartrate (IS) •Kitasamycin Tartrate (PH: JP XV)
Antibacterial properties and erythromycin approximation of gram-positive bacteria, such as Staphylococcus aureus,
Streptococcus pyogenes, green streptococcus, Streptococcus pneumoniae, tetanus, diphtheria bacilli have a strong
inhibitory effect. Gram-negative bacteria, such as Neisseria gonorrhoeae, pertussis bacteria and other gram-negative
bacteria also have considerable extent. In addition, mycoplasma, leptospirosis, rickettsial inhibition. For most resistant
to penicillin and erythromycin are effective S. aureus is the product characteristics.
medicine use
Clinical mainly for upper respiratory tract infections, pneumonia, gonorrhea, cholecystitis,
whooping cough, tonsillitis and sepsis.
Dosage and Administration
0.8g ~ 1.2g / day, orally 4 times. Leucomycin tartrate injection for intravenous injection, dose 1 0.2g,
every 6 to 8 hours. Slow intravenous injection.
You must be logged in to post a review.
Reviews
There are no reviews yet.